Disruptive Pharma AB
5LH0
Company Profile
Business description
Disruptive Pharma AB is a Swedish drug delivery technology company developing and commercializing Formulite, a patented platform based on mesoporous magnesium carbonate (MMC). The platform is designed to improve the solubility, oral bioavailability and other properties of pharmaceutical compounds. The company's business model is based on contract development, partnerships and licensing arrangements with pharmaceutical and biotechnology companies for the development and commercialization of drug products optimized with Formulite.
Contact
Dag Hammarskjold Road 54B
Uppsala Science Park
Uppsala752 37
SWESector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
Stocks News & Analysis
stocks
3 charts on Anthropic’s historic IPO filing
As Anthropic prepares to sell stock to the public, the S-1 reveals important information for investors on revenue growth, profitability, and adoption.
stocks
Weight loss drugs not an existential threat to undervalued ASX share
A durable growth story despite GLP-1 headwinds.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,018.00 | 49.20 | 0.55% |
| CAC 40 | 7,887.14 | 39.82 | 0.51% |
| DAX 40 | 25,590.77 | 179.93 | 0.71% |
| Dow JONES (US) | 52,377.57 | 15.99 | 0.03% |
| FTSE 100 | 10,686.54 | 80.79 | -0.75% |
| HKSE | 23,083.99 | 42.67 | 0.19% |
| NASDAQ | 26,477.81 | 308.43 | 1.18% |
| Nikkei 225 | 64,124.64 | 856.27 | 1.35% |
| NZX 50 Index | 13,725.60 | 45.33 | 0.33% |
| S&P 500 | 7,722.60 | 45.83 | 0.60% |
| S&P/ASX 200 | 8,895.10 | 45.00 | 0.51% |
| SSE Composite Index | 3,676.92 | 28.62 | 0.78% |